摘要
目的:评价阿立哌唑与利培酮治疗精神分裂症的药物经济学价值。方法:采用循证医学方法,将符合纳入标准的国内有关阿立哌唑与利培酮治疗精神分裂症对照研究文献的相关数据进行Meta分析,用治疗后阳性与阴性症状量表(PANSS)总分(E1)和有效率(E2)2种指标判断效果,直接药费成本当作成本。结果:阿立哌唑与利培酮的成本分别为(639.86±197.73)、(694.69±186.60)元,2种药物治疗精神分裂症的E1、E2均无显著性差异(P>0.05)。最小成本分析表明,两者的平均成本相当。结论:阿立哌唑与利培酮治疗精神分裂症的经济学价值无差异。
OBJECTIVE：To evaluate the pharmacoeconomic effectiveness of aripiprazol vs.risperidone in the treatment of schizophrenia. METHODS：The related data of the control study of aripiprazol and risperidone in the treatment of schizophrenia that meet the inclusion criteria were subjected to meta- analysis using evidence- based medicine method .The effectiveness was evaluated with total scores of PANSS （E1） after treatment and the effective rate（E2） as two indexes,and the direct drug costs were computed as costs. RESULTS： The average costs of aripiprazol and resperidone were（ 639.86 ± 197.73） yuan and （ 694.69 ± 186.60） yuan, respectively.There were no significant differences in both E1 and E2 between the two groups（P 〉0.05）. Cost minimization analysis showed that there was no significant difference in the average costs between aripiprazol and risperidone（P 〉 0.05） .CONCLUSION ：There is no pharmacoeconomic difference between aripiprazol and risperidone in the treatment schizophrenia.
出处
《中国药房》
CAS
CSCD
北大核心
2007年第29期2249-2251,共3页
China Pharmacy
